Apoquel Chewable (oclacitinib chewable Tablet) for Dogs, 3.6 mg, 30 Tablets

Apoquel Chewable (oclacitinib chewable Tablet) for Dogs, 3.6 mg, 30 Tablets

#1 Prescribed Oral Medicine for Allergic Itch¹: Apoquel Chewable (oclacitinib chewable tablet) is a revolutionary oral medicine for dogs with allergic itch. Apoquel can be used short-term or for long-term maintenance therapy²𝄒³ in dogs 12 months of age and older. Apoquel Chewable is expected to provide comparable efficacy to Apoquel Tablet after the first dose, and comparable safety to Apoquel Tablet.⁴𝄒⁵ Stops Allergic Itch at the Source⁶: Apoquel is not a steroid, antihistamine, or cyclosporine (a type of drug that reduces immune system activity). Apoquel is in a different category of medications. Unlike other medicines, Apoquel blocks allergic itch at the source. So, it works at the underlying cause of itch to provide relief fast. Fast-Acting Allergy Itch Relief: If your dog is scratching, licking, or chewing like crazy, you want to provide fast, effective relief. Apoquel Chewable controls it within 24 hours². Can be used with many other medications² including: nonsteroidal anti-inflammatory drugs (NSAIDs), vaccines (such as rabies), and allergen-specific immunotherapy (allergy shots or drops). The use of Apoquel has not been evaluated in combination with other systemic immunosuppressants, such as corticosteroids and cyclosporine. Available in Three Strengths: Apoquel Chewable comes in 3.6 mg, 5.4 mg, and 16 mg based on your dog’s body weight. Follow your veterinarian’s instructions for dosing as prescribed. You can administer to your dog orally once a day. Apoquel Chewable is a tasty pork-liver flavor. Apoquel is also available in a tablet formulation. Apoquel Chewable controls itching (pruritis) associated with allergic dermatitis and control atopic dermatitis in dogs at least 12 months of age. Apoquel is the #1 prescribed oral medicine for allergic itch and Apoquel Tablet is #1 in pet owner and vet satisfaction for oral medications for allergic itch in dogs.¹𝄒⁷𝄒⁸𝄒* Apoquel goes right to the source to help stop itching and relieve associated inflammation in affected canines controlling itch within 24 hours.² Apoquel is given twice daily for up to 14 days, and then given once daily for maintenance therapy. You can use for both short-term or long-term therapy in your dog and discontinue use without tapering. Since Apoquel is neither a steroid nor an antihistamine, your dog will avoid many of the unpleasant side effects that are often associated with them. In a 5-year safety review, the most common individual side effects reported with Apoquel were vomiting, diarrhea, lethargy, anorexia, and bloodwork changes.⁹ The most common reported side-effects occurred at a rate of less than one dog reacting out of 10,000 dogs treated.¹⁰ Apoquel Chewable is a pork-liver flavor designed to taste good and make administration easier if your dog is difficult to pill. It's scored and comes in three strengths. Both Apoquel Tablet and Apoquel Chewable are available by prescription only. Talk to your veterinarian about which is best for your dog.
References:
*Vets, n=250, Pet Owners, n=491
1. Data on file, PetTrak Total Unique Patient Count, December 2022, Zoetis Inc. (TI-09437)
2. Data on file: Study Report A161C-US-21-C02, Zoetis Inc., 2022 (TI-09898)
3. Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26(3):171-179, e35. doi:10.1111/vde.12194 (AR-01949)
4. Data on file: Study Report A461N-US-21-B66, Zoetis Inc. 2022
5. FOI Apoquel Chewable FOI Summary: 2023/06/09 Original NADA 141-555 (v2.0).
6. Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Therapy. 2014;37(4)317-24. doi:10.1111/jvp.12101 (AR-00542)
7. Data on file, Apoquel Cytopoint Vet Tracker Wave 11 (December 20 2018) (TI-04447)
8. Data on file, APOQUEL/CYTOPOINT Pet Owner Tracker Wave 11, 2022, Zoetis Inc. (TI- 08418)
9. Data on file. A Five-Year Post-Approval Safety Review for Apoquel in the US (May 2013 to August 2018), Zoetis Inc (TI-04506)
10. Volume 6C Summary of the Product Characteristics: SPC European Commission, Brussels. 1 Vol. 6C. July 10, 2006, 1-11. (AR-08728)

IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticostero